Fundraising FoxAltium Capital — Full Portfolio
27 tracked investments · listed companies and verified rows first
Delcath Systems is a commercial-stage interventional oncology company developing minimally-invasive treatments for patients with primary and metastatic liver cancers.
BiotechHealthtechMedical DevicesNy, US
Barbra Keck(Executive Officer)inJennifer Simpson(Executive Officer, Director)inGerard Michel(Chief Executive Officer (CEO) and Director)inMarco Taglietti(Director)
BoardRoger Stoll(Director)William Rueckert(Director)
Hyperfine develops diagnostic imaging and data solutions for patient care.
AI & Machine LearningDeep TechHealthtechMedical Devices
Jonathan Rothberg(Founder)Maria Sainz(President, Chief Executive Officer and Director)Brett Hale(Chief Administrative Officer, Chief Financial Officer, Treasurer and Corporate Secretary)Thomas Teisseyre(Chief Operating Officer)
Co-investorsColle Capital PartnersDolby Family Ventures
Sagimet is a clinical-stage biopharmaceutical company developing therapies targeting fatty acid synthase (FASN) for metabolic diseases and oncology.
BiotechDigital HealthHealthtechMenlo Park, US
Rekha Hemrajani(Executive Officer)inMerdad Parsey(Executive Officer, Director)inDavid Happel(Chief Executive Officer & Director)Andreas Grauer(Chief Medical Officer)inThierry Chauche(Chief Financial Officer)inMarie O'Farrell(Chief Scientific Officer)in
Co-investorsHM Venture PartnersKleiner PerkinsNew Enterprise Associates (NEA)BAM ElevateBiotechnology Value FundBlue Owl Capital+1 more
Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program.
BiotechHealthtechMendham, US
Gregory Mayes(Executive Officer, Director)Douglas Mayers(Executive Officer)inTamra Adams(Executive Officer)inAbel De La Rosa(Director)
BoardIyona Rajkomar(Director)inBenjamin Rovinski(Director)
Co-investorsAisling CapitalAvego BioScience CapitalLifeSci Venture PartnersPontifax Venture CapitalAmzak HealthDelos Capital+8 more
Chemomab is a clinical-stage biotech developing therapies that target the CCL24 cytokine involved in fibro-inflammatory diseases, with its lead antibody nebokitug tested in conditions including primary sclerosing cholangitis, systemic sclerosis, MASH and idiopathic pulmonary fibrosis.
BiotechHealthtechTel Aviv
Adi Mor(Executive Officer, Director)inAdi Mor George(Executive Officer, Director)Jill Quigley(Director)inSigal Fattal(Executive Officer)inMatthew Frankel(Executive Officer)inArnon Aharon(Executive Officer)in
Co-investorsOrbiMedSBI JI Innovation Advisory Ltd.
eGenesis uses gene editing and genome engineering to develop porcine donor animals for cross-species organ transplantation, addressing organ failure treatment and transplant supply constraints.
BiotechDeep TechMedical Devices
Mike Curtis, Ph.D.(President & Chief Executive Officer)
Co-investorsAlta PartnersEisai Innovation, Inc.Fresenius Medical Care VenturesKhosla VenturesLux Capital
Biotechnology company using multiplex gene editing to develop genetically engineered porcine organs for human transplantation.
BiotechBrookline, US
Luhan Yang(President, Secretary and Treasurer)Geoff MacKay(Chief Executive Officer)
BoardGeorge M. Church(Director)
Co-investorsAlta PartnersARCH Venture PartnersCatalio Capital Management, LPHBM Healthcare InvestmentsHBM PartnersKhosla Ventures+13 more
Precision medicine company developing therapeutics for genetically-defined age-related macular degeneration.
BiotechCambridge, US
James McLaughlin(Executive Officer, Director)in
BoardJean George(Director)Jason Rhodes(Director)inCarl Gordon(Director)in
Co-investorsLightstone VenturesAtlas VentureOrbiMed
OLG Machinery, founded in 2008, trades new and certified used industrial spare parts and machinery, serving U.S. companies operating across North and South America with a focus on Mexico.
Advanced ManufacturingB2B MarketplacesLogistics & Supply Chain
Co-investorsOxford Investment Opportunity Network (OION)Ally Bridge GroupAmgen VenturesDroia VenturesFrazier Healthcare PartnersNovo Holdings+2 more
Hummingbird Bioscience is a precision biotherapeutics company developing a pipeline of novel targeted therapies for cancer, using proprietary drug discovery technologies and platforms.
AI & Machine LearningBiotechDeep TechHealthtech
Piers Ingram(Chief Executive Officer, Co-Founder, Executive Director)inJerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)inKonrad Paszkiewicz(Chief Technology Officer)inKwek Kon Yew(Chief Medical Officer)Dipti Thakkar(Chief Operating Officer)in
Co-investorsClavystBioDecheng CapitalDroia VenturesFrazier Life SciencesKiwoom InvestmentMuirwoods Ventures+6 more
Immunovant is a clinical-stage immunology company developing targeted therapies based on anti-FcRn technology for people with autoimmune diseases.
BiotechHealthtechMedical DevicesNew York, US
Christopher Van Tuyl(Executive Officer)Michael Geffner(Executive Officer)inPete Salzmann(Executive Officer, Director)inJay Stout(Executive Officer)inMelanie Gloria(Executive Officer)inEva Renee Barnett(Executive Officer)
Opus Genetics (formerly Ocuphire) is a clinical-stage ophthalmic biopharmaceutical company developing gene therapies and other treatments for inherited retinal diseases (IRDs) and other retinal and refractive disorders.
BiotechDeep TechDigital HealthWest Bloomfield, US
Mina Sooch(Executive Officer, Director)Meyer Alan(Director)
Co-investorsCapital Midwest FundID Ventures
Palisade Bio develops a PDE4 prodrug platform for treating immune, inflammatory, and fibrotic diseases, with improved pharmacokinetics and tolerability compared to traditional PDE4 inhibitors.
BiotechMedical DevicesCarlsbad, US
I. Richard Garr(Executive Officer, Director)Karl Johe(Executive Officer, Director)Robert McRae(Executive Officer)inHerbert Slade(Executive Officer)J.D. Finley(Executive Officer, Director)JD Finley(Chief Executive Officer)
Quoin Pharmaceuticals is a pharmaceutical company developing therapeutic products for rare diseases, with a lead candidate, QRX003, in clinical trials for Netherton Syndrome.
BiotechHealthtechAshburn, US
Michael Myers(Executive Officer, Director)Denise Carter(Executive Officer, Director)inMICHAEL MEYERS(Executive Officer, Director)Sally Bridget Lawlor(Executive Officer)Eyal Leibovitz(Executive Officer)Shai Yarkoni(Executive Officer, Director)
BiotechNew York, US
Raj Mehra(Chief Executive Officer)Michael Golembiewski(Chief Financial Officer)inBRIAN DORSEY(Executive Officer)CATHERINE BOVENIZER(Executive Officer)NEIL MORTON(Executive Officer)
BoardBrian Lian(Director)
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
CerevelCerevel TherapeuticsQuoinSonnet BiotherapeuticsSonnetbioTimber PharmaceuticalsTimberpharmaVincerxVincerx PharmaYumanityYumanity Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.